Skip to content
value.today

Atlas Therapeutics Corp

Total raised
$50 M
3 rounds on record
Latest round
$40 M
Apr 2022
First round on record
Jul 2012
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Atlas Therapeutics Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2022$40 MNo. 3$10 to $50 million

Atlas Therapeutics Corp: Raise no. 3, Apr 2022

Investors in this round

9 investors had bought by the notice of Apr 19, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $79 M offered; $39 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Edward Doerr · Executive Officer, Director
  • Ramona Edward Seabaugh · Executive Officer
  • Gerald C. Gradwell · Director
  • Glen R. Stettin · Director
  • Laurie R. McGraw · Director
  • Michael R. Kramer · Director
  • Paul D. Johnson · Director
  • Robert C. Faulkner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in CA, IL, NY, and outside the US

Signed by Ramona Seabaugh, Chief Financial Officer. Newest notice filed Apr 19, 2022. Read the notice at the SEC.

equity, optionsSEC
Jan 2014$5 MNo. 2$2 to $10 million

Atlas Therapeutics Corp: Raise no. 2, Jan 2014

Investors in this round

32 investors had bought by the notice of Feb 6, 2014: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Carl J. DeFreitas · Executive Officer, Director
  • Peter Levy · Executive Officer
  • Buzz J. Aldrin · Director
  • Louis J. Aronne · Director
  • Peter J. Diamandis · Director
  • Robert J. Hariri · Director
  • Sapna J. Srivastava · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Brean Capital, LLC (CRD 23723) · New York, New YorkSold in CT, MA, MD, NJ, NV, NY, TX

Remarks in the notice

  • On fees: “The placement agent received shares of the Issuer's common stock and no cash commissions.”

Signed by Peter Levy, President. Newest notice filed Feb 6, 2014. Read the notice at the SEC.

equity, optionsSEC
Jul 2012$6 MNo. 1$2 to $10 million

Atlas Therapeutics Corp: Raise no. 1, Jul 2012

Investors in this round

55 investors had bought by the notice of Jul 11, 2012: 55 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$178,800
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Peter Levy · Executive Officer
  • Buzz J. Aldrin · Director
  • Louis J. Aronne · Director
  • Peter J. Diamandis · Director
  • Robert J. Hariri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Chardan Capital Markets, LLC (CRD 120128) · New York, New YorkSold in IL, MD, NY, PA

Remarks in the notice

  • On fees: “The placement agent received a commission on the aggregate purchase price paid by investors it introduced to the issuer.”

Signed by Peter Levy, Chief Operating Officer. Newest notice filed Jul 11, 2012. Read the notice at the SEC.

equitySEC
Feb 2011$1 MIssued in a merger or acquisitionUnder $2 million

Atlas Therapeutics Corp: Private sale, Feb 2011

Investors in this round

4 investors had bought by the notice of Mar 8, 2011: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$450,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Carlon Colker, MD, FACN · Executive Officer
  • J.B. Bernstein · Executive Officer, Director
  • Georgette Mathers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Consideration for assets purchased from seller who simultaneously became an executive officer of the Issuer.”
  • On a merger: “Please see the Issuer's Form 8-K filed with the SEC on EDGAR on March 3, 2011.”

Signed by J.B. Bernstein, Chief Executive Officer. Newest notice filed Mar 8, 2011. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Atlas Therapeutics Corp chose not to state its revenue in its newest notice of a funding round (Apr 2022).

    SEC Form D · Apr 2022

  • Revenue range over time, as stated in its notices: no revenue in 2011; revenue of up to $1 million in 2012; revenue between $1 million and $5 million in 2014.

    SEC Form D (revenue range) · Feb 2014

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Apr 2022

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Atlas Therapeutics Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Atlas Therapeutics Corp
NameRoleNamed in
Mark Edward DoerrExecutive officerApr 2022
Ramona Edward SeabaughExecutive officerApr 2022
Carl J. DeFreitasExecutive officerFeb 2014
Peter LevyExecutive officerFeb 2014
Carlon Colker, MD, FACNExecutive officerMar 2011
J.B. BernsteinExecutive officerMar 2011
Gerald C. GradwellDirectorApr 2022
Glen R. StettinDirectorApr 2022
Laurie R. McGrawDirectorApr 2022
Mark Edward DoerrDirectorApr 2022
Michael R. KramerDirectorApr 2022
Paul D. JohnsonDirectorApr 2022
Robert C. FaulknerDirectorApr 2022
Buzz J. AldrinDirectorFeb 2014
Carl J. DeFreitasDirectorFeb 2014
Louis J. AronneDirectorFeb 2014
Peter J. DiamandisDirectorFeb 2014
Robert J. HaririDirectorFeb 2014
Sapna J. SrivastavaDirectorFeb 2014
Georgette MathersDirectorMar 2011
J.B. BernsteinDirectorMar 2011

About

American pharmacy technology company, formerly Nasdaq-listed (MDVL); filed for Chapter 7 bankruptcy in 2024.